Pridopidine’s effects on respiration and bulbar function align with previously reported effects of the non-selective S1R agonist Nuedexta® (20 mg dextromethorphan + 10 mg quinidine) on swallowing and saliva control, further supporting the potential of the S1R as a therapeutic target in ALS [164,165]. The gene discussed is TMBIM4; the disease is amyotrophic lateral sclerosis.